Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
Authors' conclusion
The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted.
Study context
- Population
- Adults with insulin-treated T2D using basal-bolus insulin therapy, categorized by CMS C-peptide criteria: high C-peptide and low C-peptidehigh C-peptide 195 · low C-peptide 59
- Comparison
- Automated insulin delivery (AID) vs control, by C-peptide level
Methodological detailssubgroup analysis by C-peptide level
- Subgroup analysis by C-peptide level
Primary result
As reported in the abstract
HbA1c change from baseline, by C-peptide subgroup
Mean HbA1c decrease from baseline with AID
0.8%
Further findings
HbA1c in participants ≥65 years old
- Results were similar in participants ≥65 years old
Original publication
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level. Diabetes Care. Published 15 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →